MedPath

Gabapentin

Generic Name
Gabapentin
Brand Names
Gralise, Neurontin
Drug Type
Small Molecule
Chemical Formula
C9H17NO2
CAS Number
60142-96-3
Unique Ingredient Identifier
6CW7F3G59X

Overview

Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.. It is structurally and functionally related to another GABA derivative, pregabalin.

Background

Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures - today it is also widely used to treat neuropathic pain. Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.. It is structurally and functionally related to another GABA derivative, pregabalin.

Indication

In the United States, gabapentin is officially indicated for the treatment of postherpetic neuralgia in adults and for the adjunctive treatment of partial-onset seizures, with or without secondary generalization, in patients 3 years of age and older. In Europe, gabapentin is indicated for adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalization, in patients 6 years of age and older and as monotherapy in patients 12 years of age and older. It is also used in adults for the treatment of various types of peripheral neuropathic pain, such as painful diabetic neuropathy.

Associated Conditions

  • Partial-Onset Seizures
  • Peripheral Neuropathic Pain
  • Postherpetic Neuralgia

Clinical Trials

FDA Approved Products

GABAPENTIN
Manufacturer:DIRECT RX
Route:ORAL
Strength:400 mg in 1 1
Approved: 2023/06/28
NDC:72189-113
Gabapentin
Manufacturer:Preferred Pharmaceuticals, Inc.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/06/29
NDC:68788-7757
Gabapentin
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:300 mg in 1 1
Approved: 2021/02/16
NDC:63629-7962
GABAPENTIN
Manufacturer:Ascent Pharmaceuticals, Inc
Route:ORAL
Strength:600 mg in 1 1
Approved: 2021/10/05
NDC:43602-466
Gabapentin
Manufacturer:Bryant Ranch Prepack
Route:ORAL
Strength:800 mg in 1 1
Approved: 2020/10/20
NDC:71335-1007

Singapore Approved Products

Gabapentin Sandoz Capsules 400mg
Manufacturer:Sandoz Private Limited, Kalwe Site
Form:CAPSULE
Strength:400mg
Online:Yes
Approved: 2009/07/20
Approval:SIN13678P
PMS-GABAPENTIN CAPSULE 100 mg
Manufacturer:PHARMEL INC
Form:CAPSULE
Strength:100 mg
Online:Yes
Approved: 2005/01/14
Approval:SIN12638P
ALPENTIN CAPSULE 300MG
Manufacturer:PT Actavis Indonesia
Form:CAPSULE
Strength:300 mg
Online:Yes
Approved: 2023/02/15
Approval:SIN16697P
GABAPIN 300-GABAPENTIN CAPSULES USP 300 MG
Manufacturer:Intas Pharmaceuticals Limited
Form:CAPSULE, GELATIN COATED
Strength:300 mg
Online:Yes
Approved: 2021/07/30
Approval:SIN16293P
ALPENTIN CAPSULE 100MG
Manufacturer:PT Actavis Indonesia
Form:CAPSULE
Strength:100 mg
Online:Yes
Approved: 2023/02/15
Approval:SIN16698P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath